Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Oxford University

- PMLiVE

New Swedish study finds HSCT can slow progression of multiple sclerosis

More than 70% of participants in the study had no new progression after five years of treatment

- PMLiVE

NIHR partners with Motor Neurone Disease Association for MND research

The partnership will speed up the discovery of treatments and insights for MND

- PMLiVE

AbbVie announces acquisition of Mitokinin in deal worth over $650m

The agreement gives AbbVie access to a potential treatment for Parkinson’s disease

- PMLiVE

Alzheimer’s Research UK awards Cardiff University researchers £387,000

The researchers will investigate how genes accelerate the development of Alzheimer’s disease

- PMLiVE

Alzheimer’s Research UK launches ‘Change The Ending’ campaign

A survey revealed that 22% of 2,162 people were unaware of the impact dementia has on people’s everyday lives

- PMLiVE

Researchers discover how neurons die in Alzheimer’s disease

The findings open up potential avenues to develop new treatments for the condition

- PMLiVE

MJFF awards Nine Square Therapeutics $4.5m for Parkinson’s disease research

The research grant will help to identify drug candidates for the treatment of the disease

- PMLiVE

AstraZeneca’s rare disease unit partners with Verge Genomics in deal worth over $840m

Both will identify drug targets for neurodegenerative and neuromuscular diseases

- PMLiVE

New blood test could one day be used to diagnose Parkinson’s disease

The discovery could potentially lead to the development of a definitive diagnostic test

- PMLiVE

International survey reveals varying effects of oral medicines for Parkinson’s

More than 65% of respondents reported variations in the effects of taking oral medications

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

Study reveals gut conditions could be early sign of Parkinson’s disease

Constipation, dysphagia and IBS could be potential biomarkers of the condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links